[1]李兴媚,罗娜,关郁,等.卡铂联合杨梅素对人卵巢癌HO-8910 PM细胞侵袭、转移及MAPK/ERK通路的影响[J].中国计划生育和妇产科,2018,(12):86-90.
 LI Xing-mei,LUO Na,GUAN Yu,et al.Effects of carboplatin combined with myricetin on invasion, metastasis and MAPK/ERK pathway in human ovarian cancer HO-8910PM cells[J].Chinese Journal of Family Planning & Gynecotokology,2018,(12):86-90.
点击复制

卡铂联合杨梅素对人卵巢癌HO-8910 PM细胞侵袭、转移及MAPK/ERK通路的影响
分享到:

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

卷:
期数:
2018年12期
页码:
86-90
栏目:
论著与临床
出版日期:
2018-12-25

文章信息/Info

Title:
Effects of carboplatin combined with myricetin on invasion, metastasis and MAPK/ERK pathway in human ovarian cancer HO-8910PM cells
作者:
李兴媚1罗娜2关郁1刘丹3*梅庆步3董冰1
161000黑龙江齐齐哈尔,齐齐哈尔医学院,1.附属第三医院妇产科;2.附属第三医院超声科;3. 基础医学院遗传学教研室
Author(s):
LI Xing-mei1 LUO Na2GUAN Yu1LIU Dan3* MEI Qing-bu3 DONG Bing1
1. Department of Gynecology and Obstetrics, the Third Affiliated Hospital of Qiqihar Medical School;2. Department of Ultrasound,the Third Affiliated Hospital of Qiqihar Medical School;3. Department of Genetics and Research, School of Basic Medicine, Qiqih
关键词:
卡铂杨梅素卵巢癌HO-8910 PM细胞侵袭、转移MAPK/ERK
Keywords:
carboplatin myricetin ovarian cancer HO-8910 PM cells invasion and metastasis mitogen activated protein kinase / extracellular signal-regulated kinase pathway(MAPK/ ERK pathway)
分类号:
R 71175
摘要:
目的探究卡铂联合杨梅素对人卵巢癌HO-8910 PM细胞侵袭、转移及丝裂原活化蛋白激酶(mitogen activated protein kinase,MAPK)/细胞外信号调节激酶(extracellular signal-regulated protein kinase,ERK)通路的影响。方法体外培养人卵巢癌HO-8910 PM细胞,以不进行处理的细胞作为正常组,分别用5、20、50 μmol/L卡铂,20、40、60 mg/L杨梅素以及两者联合处理,MTT法筛选联合处理最佳浓度,Transwell侵袭实验检测HO-8910 PM细胞侵袭能力变化情况,划痕实验检测细胞转移能力,RT-PCR检测HO-8910 PM细胞伤害性信息与即刻早期基因c-fos、细胞增殖相关基因反式作用因子激活蛋白c-Jun、基质金属蛋白酶(matrix metallopeptidase 9, MMP-9)表达,Western blot检测细胞外调节蛋白激酶(ERK 1/2)、p-ERK 1/2、c-fos、c-jun、活化蛋白转录因子-1(activator protein-1,AP-1)、MMP-9蛋白的表达。结果卡铂、杨梅素单独处理时,细胞抑制率呈剂量依赖性升高,卡铂20 μmol/L联合杨梅素60 mg/L处理细胞时(联合组),细胞抑制率最高为(8469±1419)%(P<005)。与正常组、卡铂20 μmol/L、杨梅素60 mg/L组相比,联合组穿膜细胞数量显著降低,迁移抑制率显著升高(P<005)。RT-PCR检测结果显示联合组 c-fos、c-jun、MMP-9 mRNA表达量均显著低于正常组、卡铂20 μmol/L、杨梅素60 mg/L处理组(P<005)。联合组p-ERK 1/2、c-fos、c-jun、AP-1、MMP-9蛋白表达量均显著低于正常组、卡铂20 μmol/L、杨梅素60 mg/L处理组(P<005)。结论卡铂联合杨梅素可明显抑制人卵巢癌HO-8910 PM细胞侵袭、转移,其机制可能与抑制MAPK/ERK通路有关。
Abstract:
ObjectiveTo explore the effects of carboplatin combined with myricetin on invasion, metastasis and mitogen activated protein kinase (MAPK) / extracellular signal-regulated kinase (ERK) pathway in human ovarian cancer HO-8910 PM cells. MethodsHuman ovarian cancer HO-8910 PM cells were cultured in vitro, and the untreated cells were used as normal group, and treated with 5, 20, 50 μmol/L carboplatin, 20, 40, 60 mg/L myricetin and the two combined, respectively, and screened by MTT method. The optimal concentration of combined treatment was screened by MTT method. The invasive ability of HO-8910 PM cells was detected by Transwell invasion assay. The cell transfer ability was detected by scratch test. Used the RT-PCR to detect the HO-8910 PM cell injury information and immediate early gene (c-fos), cell proliferation related gene trans acting factor activating protein (c-Jun) and matrix metalloproteinase (MMP)-9 expressions, the expressions of extracellular regulated protein kinase (ERK1/2), p-ERK1/2, c-fos, c-jun, activated protein transcription factor-1 (AP-1) and MMP-9 protein were detected by Western blot. ResultsWhen carboplatin and myricetin were treated separately, the cell inhibition rate increased in a dose-dependent manner, the highest cell inhibition rate was (8469 ± 1419)% when the 20 μmol/L carboplatin combined with 60 mg/L myricetin treated, which was significantly higher than that of the separate treatment (P< 005).Compared with the normal group, carboplatin 20 μmol/L and myricetin 60 mg/L treatment group, the number of penetrating cells in the combined group decreased significantly, and the migration inhibition rate increased significantly (P< 005).RT-PCR showed that the expression levels of c-fos, c-jun and MMP-9 mRNA in combined group were significantly lower than those in the normal group, carboplatin 20 μmol/L and myricetin 60 mg/L treatment group (P< 005).The expression of p-ERK 1/2, c-fos, c-jun, AP-1 and MMP-9 protein in the combined group were significantly lower than those of the normal group, the carboplatin 20 μmol/L and the myricetin 60 mg/L treatment group (P< 005).ConclusionCarboplatin combined with myricetin can significantly inhibit the invasion and metastasis of human ovarian cancer HO-8910 PM cells, and the mechanism may be related to the inhibition of the MAPK/ERK pathway.

参考文献/References:

[1]银琪,生秀杰.子宫内膜异位症相关卵巢癌病因研究进展 [J].国际妇产科学杂志,2016,43(6):681-685. [2]林镇海,闫士灿,张洁筠,等.MST 4通过激活MAPK-ERK信号通路调节炎症因子释放促进肝癌的侵袭和转移的机制研究 [J].中国癌症杂志,2017,27(9):681-686. [3]刘丹,郑立红,李兴媚.卡铂通过抑制ERK 1/2通路诱导人卵巢癌细胞S和G_1期阻滞 [J].中国生物化学与分子生物学报,2014,30(8):815-823. [4]张秀娟,侯喆,白雪莹,等.杨梅素作用于人肝癌HepG-2细胞凋亡信号转导途径的研究 [J].中国药理学通报,2014,30(1):71-76. [5]李文军,康红兵,杨立,等.延龄草皂苷通过NF-κB/MAPK信号通路调控MMPs表达并抑制骨肉瘤Saos-2细胞的迁移和侵袭 [J].肿瘤,2016,36(9):968-976. [6]曾峰,谭永嘉,曾庆良.乳腺癌MAPK通路中pMEK蛋白在TE方案新辅助治疗中的变化 [J].重庆医学,2012,41(26):2757-2758. [7]刘伟,黄玮,李瑞琴.MAPK/ERK 信号传导通路与肿瘤发生的相关机制研究进展 [J].中国现代医药杂志,2016,18(8):97-100. [8]邓琳,冯定庆,凌斌.环氧化酶2抑制剂抗卵巢癌作用的研究进展 [J].现代妇产科进展,2015,24(11):876-878. [9]冯江,陈立军.培美曲塞或吉西他滨联合卡铂治疗晚期非小细胞肺癌的临床疗效及安全性评价 [J].中国临床药理学杂志,2015,31(13):1230-1232. [10]吴少花,陈君,刘亚萌,等.杨梅素抗肿瘤活性研究进展 [J].吉林医药学院学报,2015,36(5):381-383. [11]顾蔚卿,兰文静,陈斌,等.贝伐单抗联合紫杉醇/卡铂治疗晚期非鳞状细胞型非小细胞肺癌44例临床分析 [J].肿瘤,2013,33(12):1081-1086. [12]孙大永,左彦珍,梁鸿鹄,等.二氢杨梅素对肺癌A 549细胞凋亡的作用 [J].解剖学报,2015,46(3):359-362. [13]卞杰,顾明,侯胜燕,等.杨梅素抗肝肿瘤细胞HepG 2作用及其机制的研究 [J].中国医药导报,2012,9(36):7-9. [14]陈茜,陈丽娟,党媛媛,等.姜黄素通过阻滞MAPK/ERK通路抑制人子宫内膜癌HEC-1-B细胞的侵袭转移 [J].山西医科大学学报,2015,46(8):762-768. [15]张勇,张启发,田长海,等.ITGB 1通过激活MAPK/ERK通路促进前列腺癌细胞侵袭 [J].国际泌尿系统杂志,2017,37(3):329-331. [16]柴成梁,王晓慧,崔燕,等.脂质体多柔比星联合卡铂治疗卵巢癌疗效及安全性的系统评价 [J].实用妇产科杂志,2014,30(7):526-530. [17]王想福,孙凤歧,叶丙霖,等.类黄酮对人体外周血破骨细胞分化p38MAPK/c-Fos信号通路调控的研究 [J].中国骨质疏松杂志,2017,23(11):1488-1491, 1529. [18]马一平.异长春花碱抑制人乳腺癌细胞转移侵袭的作用及其机制 [J].中草药,2013,44(13):1786-1792. [19]李明,彭解英,吴颖芳,等.槟榔碱诱导上皮细胞基质金属蛋白酶9表达上调的分子机制 [J].国际口腔医学杂志,2015,42(2):166-169. [20]刘博,戚诚,刘学臣,等.AFAP-1L2对胰腺癌细胞侵袭及转移的影响及机制 [J].中国普通外科杂志,2015,24(9):1257-1262.

相似文献/References:

[1]张雪梅.紫杉醇联合洛铂化疗方案对晚期初治卵巢癌术后 患者早期临床疗效及毒副反应发生率的分析[J].中国计划生育和妇产科,2018,(2):72.
 ZHANG Xue-mei.Early clinical efficacy and side effects of paclitaxel combined with lobaplatin regimen on postoperative patients with advanced ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(12):72.

备注/Memo

备注/Memo:
黑龙江省教育厅科学技术研究项目(项目编号:12541915)
更新日期/Last Update: 2018-12-25